Covenant Waiver Extension

Summary by AI ^BETAClose X

Litigation Capital Management Limited has secured an extension of its debt covenant waiver from Northleaf until May 30, 2026, with the existing 2.00% per annum interest increase remaining in effect without any additional waiver fee. This extension supports the ongoing Strategic Review, initiated on September 15, 2025, which aims to resolve the company's capital position, and reflects Northleaf's continued support.

Disclaimer*

Litigation Capital Management Ltd

15 April 2026

Litigation Capital Management Limited

("LCM" or the "Company")

Covenant Waiver Extension

Litigation Capital Management Limited ("LCM"), an alternative asset manager specialising in dispute financing solutions internationally, announces that the debt covenant waiver from Northleaf that was due to expire on 15 April 2026 has been extended to 30 May 2026. During the extended waiver period the interest on the loan remains increased by 2.00% per annum consistent with the initial waiver. There is no additional one-time waiver fee in relation to this extension.

The Strategic Review that was first announced on 15 September 2025 continues to progress and this waiver extension is reflective of Northleaf's ongoing support while LCM works towards a long-term resolution of its capital position. LCM management will provide an update on the progress of the Strategic Review in due course.

Enquiries

Litigation Capital Management
Patrick Moloney, Chief Executive Officer David Collins, Chief Financial Officer

Cavendish (Nomad and Broker)	Tel: 020 7220 0500
Jonny Franklin-Adams and Isaac Hooper (Corporate Finance) Ella Bedford (Corporate Broking)

www.lcmfinance.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END